This program project application will enable Ordway investigators to further studies of a new paradigm for robustly determining doses and schedules of drugs to treat patients infected with the Bioterror pathogens Bacillus anthracis, Yersinia pestis and the Pox viruses Vaccinia Virus and Cowpox Virus. An interdisciplinary program project will facilitate concurrent investigation of this paradigm in several pathogens and enable investigators to learn more about the pharmacodynamics of drugs intended for therapy. Because of the seriousness of these illnesses, drug doses and schedules have to be right the first time. In addition to being able to set drug exposure targets employing a validated (in bacteria as well as in multiple HIV studies) in vitro hollow fiber infection model, the investigators have developed a robust approach employing Monte Carlo simulation for translating the insights from the in vitro system and animal models to man. Ordway has the expertise locally, with our New York State Health Department relationships, and in our US Army Medical Research Institute of Infectious Diseases (USAMRIID) collaborators as well as the infrastructure support to help solve this serious national problem. In order to correctly determine the right dose for man, there are four pieces of knowledge required. The first is a drug exposure target (ADC/MIC ratio, Peak/MIC ratio, Time > MIC, etc). The second is to have a measure of the variability of the pharmacokinetics of the agent in the population. The third is to have a measure of the distribution of MIC's for different strains of the pathogen of interest for the drug in question. The final piece of knowledge is to have a measure of the impact of protein binding on the microbiological activity of the drug. The program project application will develop this required knowledge through four integrated projects: (1) Determining therapeutic regimens for Bacillus anthracis in the hollow fiber system, (2) Determining therapeutic regimens for Yersinia pestis in the hollow fiber system, (3) Determining therapeutic regimens for the Variola major surrogates Vaccinia Virus and Cow Pox in the hollow fiber system and in an animal model, and (4) Examining the predictions of the hollow fiber model system in inhalational animal models of Anthrax and Plague. These projects will be supported by analytical, computational, and administrative cores to facilitate thematic integration. The Ordway investigators have already had significant success in addressing these issues. One example is the identification of an exposure to a fluoroquinolone antimicrobial that would achieve the desired goal of therapy for Bacillus anthracis. Indeed, the predictions from the hollow fiber system were evaluated in a Balb/c mouse model at USAMRIID, as well as in a rhesus monkey challenge and shown to be correct.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI060908-03
Application #
7269441
Study Section
Special Emphasis Panel (ZAI1-JB-M (M1))
Program Officer
Xu, Zuoyu
Project Start
2005-07-15
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
3
Fiscal Year
2007
Total Cost
$1,788,209
Indirect Cost
Name
Ordway Research Institute, Inc.
Department
Type
DUNS #
124361945
City
Albany
State
NY
Country
United States
Zip Code
12208
Roberts, Jason A; Abdul-Aziz, Mohd H; Lipman, Jeffrey et al. (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498-509
Heine, Henry S; Louie, Arnold; Adamovicz, Jeffrey J et al. (2014) Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. Antimicrob Agents Chemother 58:3276-84
Louie, Arnold; Vanscoy, Brian; Liu, Weiguo et al. (2013) Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children. Antimicrob Agents Chemother 57:5946-60
Louie, Arnold; VanScoy, Brian D; Brown, David L et al. (2012) Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob Agents Chemother 56:1229-39
Louie, Arnold; Vanscoy, Brian D; Heine 3rd, Henry S et al. (2012) Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob Agents Chemother 56:513-7
Louie, A; Heine, H S; VanScoy, B et al. (2011) Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother 55:822-30
Louie, Arnold; Vanscoy, Brian; Liu, Weiguo et al. (2011) Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 55:2623-8
Bulitta, Jurgen B; Landersdorfer, Cornelia B; Forrest, Alan et al. (2011) Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol 12:2044-61
Drusano, G L; Okusanya, O O; Okusanya, A O et al. (2009) Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis. Antimicrob Agents Chemother 53:4718-25
Louie, A; Heine, H S; Kim, K et al. (2008) Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 52:2486-96

Showing the most recent 10 out of 15 publications